Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted

BACKGROUND: In 2014–2015, we assessed favipiravir tolerance and efficacy in patients with Ebola virus (EBOV) disease (EVD) in Guinea (JIKI trial). Because the drug had never been used before for this indication and that high concentrations of the drugs were needed to achieve antiviral efficacy again...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Thi Huyen Tram, Guedj, Jérémie, Anglaret, Xavier, Laouénan, Cédric, Madelain, Vincent, Taburet, Anne-Marie, Baize, Sylvain, Sissoko, Daouda, Pastorino, Boris, Rodallec, Anne, Piorkowski, Géraldine, Carazo, Sara, Conde, Mamoudou N., Gala, Jean-Luc, Bore, Joseph Akoi, Carbonnelle, Caroline, Jacquot, Frédéric, Raoul, Hervé, Malvy, Denis, de Lamballerie, Xavier, Mentré, France
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340401/
https://www.ncbi.nlm.nih.gov/pubmed/28231247
http://dx.doi.org/10.1371/journal.pntd.0005389

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340401/
https://www.ncbi.nlm.nih.gov/pubmed/28231247
http://dx.doi.org/10.1371/journal.pntd.0005389

Ejemplares similares